NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Lene Sofie Granfeldt Østgård
  • Mette Nørgaard
  • Lars Pedersen
  • René Østgård
  • Lone Smidstrup Friis, Hæmatologisk Afdeling, Rigshospitalet
  • ,
  • Claudia Schöllkopf, Medicinsk Hæmatologisk Afdeling, Herlev Hospital, Region Hovedstaden
  • ,
  • Marianne Tang Severinsen, Institut for Klinisk Medicin - Hæmatologisk Afdeling, Aalborg Sygehus
  • ,
  • Claus Werenberg Marcher, Hæmatologisk Afdeling, OUH
  • ,
  • Bruno C Medeiros, Stanford University
  • ,
  • Morten Krogh Jensen, Hæmatologisk Afdeling, Sygehus Nord, Roskilde

Background: Most cases of acute leukemia arise without identifiable risk factors. Studies investigating the impact of autoimmune diseases and infections on leukemogenesis have revealed conflicting results. If inflammation increases the risk of acute myeloid leukemia (AML), nonsteroidal anti-inflammatory drug (NSAID) use may decrease the risk of leukemia.

Methods: We conducted a case-control study of 3,053 patients with AML diagnosed between 2000 and 2013, who were registered in the Danish National Acute Leukemia Registry, and 30,530 population controls matched on sex and age. We identified prescriptions through the Danish National Health Service Prescription Database. We used conditional logistic regression analysis to compute ORs associating AML with NSAID use overall, in patients with inflammatory diseases, and for specific AML subtypes (de novo AML, AML related to previous hematological disease, ie, secondary AML [sAML], or therapy-related AML [tAML; exposed to previous cytotoxic therapy]).

Results: Overall, NSAID use was not associated with a lower risk of AML (OR 1.1, 95% CI=1.0-1.2), de novo AML (OR 1.0, 95% CI=0.9-1.1), and sAML/tAML (OR 1.3, 95% CI=1.1-1.5). In addition, in patients with known inflammatory diseases, NSAIDs did not affect AML risk (OR 0.9, 95% CI=0.5-1.6). Number of prescriptions, type of NSAID, age, or sex did not influence the results.

Conclusion: In line with our recent findings that showed no association between autoimmune diseases and infections and de novo AML, NSAID use was not found to reduce the risk of AML.

OriginalsprogEngelsk
TidsskriftCancer Management and Research
Vol/bind10
Sider (fra-til)5043-5051
Antal sider9
ISSN1179-1322
DOI
StatusUdgivet - 2018

Se relationer på Aarhus Universitet Citationsformater

ID: 142809807